Literature DB >> 12807477

Limited role of charge matching in the interaction of human immunoglobulin A with the immunoglobulin A Fc receptor (Fc alpha RI) CD89.

Richard J Pleass1, Prabhjyot K Dehal, Melanie J Lewis, Jenny M Woof.   

Abstract

Human immunoglobulin A (IgA) mediates protective effector mechanisms through interaction with specific cellular Fc receptors (Fc alpha RI). Two IgA Fc interdomain loops (Leu257-Leu258 in the CH2 domain and Pro440-Phe443 in the CH3 domain) have previously been identified as critical for binding to Fc alpha RI. On the receptor, the interaction site for IgA has been localized to the EC1 domain. The essential Fc alpha RI residues involved are Tyr35, Tyr81 and Arg82, with contributions also from Arg52 and to a lesser extent from His85 and Tyr86. The basic nature of the side chains of some of the receptor residues implicated in ligand binding suggested that charge matching might play some role in the interaction. To address this possibility, we have generated five IgA1 mutants with point substitutions in acidic residues lying close to the putative interaction site and assessed their abilities to bind Fc alpha RI on human neutrophils. Mutants E254A, E254L and E437A displayed affinities for Fc alpha RI comparable to that of wild-type IgA1, while mutants D255A and D255V had only slightly reduced affinities for the receptor. Therefore, electrostatic interactions appear unlikely to play a significant role in the IgA-Fc alpha RI interaction. Moreover, the lack of effect of mutations in residues adjacent to those previously implicated in binding, reaffirms the importance of the interdomain loops in Fc alpha RI binding.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12807477      PMCID: PMC1782991          DOI: 10.1046/j.1365-2567.2003.01677.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  29 in total

1.  The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex.

Authors:  P Sondermann; R Huber; V Oosthuizen; U Jacob
Journal:  Nature       Date:  2000-07-20       Impact factor: 49.962

Review 2.  Recombinant immunoglobulin A: powerful tools for fundamental and applied research.

Authors:  Blaise Corthésy
Journal:  Trends Biotechnol       Date:  2002-02       Impact factor: 19.536

3.  Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4.

Authors:  M P Reddy; C A Kinney; M A Chaikin; A Payne; J Fishman-Lobell; P Tsui; P R Dal Monte; M L Doyle; M R Brigham-Burke; D Anderson; M Reff; R Newman; N Hanna; R W Sweet; A Truneh
Journal:  J Immunol       Date:  2000-02-15       Impact factor: 5.422

Review 4.  IgA antibodies for cancer therapy.

Authors:  M Dechant; T Valerius
Journal:  Crit Rev Oncol Hematol       Date:  2001 Jul-Aug       Impact factor: 6.312

5.  The interaction of Fc alpha RI with IgA and its implications for ligand binding by immunoreceptors of the leukocyte receptor cluster.

Authors:  B D Wines; C T Sardjono; H H Trist; C S Lay; P M Hogarth
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

6.  In vitro characterization of five humanized OKT3 effector function variant antibodies.

Authors:  D Xu; M L Alegre; S S Varga; A L Rothermel; A M Collins; V L Pulito; L S Hanna; K P Dolan; P W Parren; J A Bluestone; L K Jolliffe; R A Zivin
Journal:  Cell Immunol       Date:  2000-02-25       Impact factor: 4.868

7.  Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha.

Authors:  S C Garman; B A Wurzburg; S S Tarchevskaya; J P Kinet; T S Jardetzky
Journal:  Nature       Date:  2000-07-20       Impact factor: 49.962

8.  A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease.

Authors:  Paul A Carpenter; Frederick R Appelbaum; Lawrence Corey; H Joachim Deeg; Kris Doney; Theodore Gooley; James Krueger; Paul Martin; Sandra Pavlovic; Jean Sanders; John Slattery; Daniel Levitt; Rainer Storb; Ann Woolfrey; Claudio Anasetti
Journal:  Blood       Date:  2002-04-15       Impact factor: 22.113

Review 9.  The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism.

Authors:  Katharine C Hsu; Shohei Chida; Daniel E Geraghty; Bo Dupont
Journal:  Immunol Rev       Date:  2002-12       Impact factor: 12.988

10.  Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

Authors:  Kevan C Herold; Joshua B Burton; Fleur Francois; Ena Poumian-Ruiz; Mariela Glandt; Jeffrey A Bluestone
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

View more
  5 in total

1.  Cloning and characterization of equine CD89 and identification of the CD89 gene in chimpanzees and rhesus macaques.

Authors:  H Craig Morton; Richard J Pleass; Anne K Storset; Per Brandtzaeg; Jenny M Woof
Journal:  Immunology       Date:  2005-05       Impact factor: 7.397

2.  Human Cell Line-Derived Monoclonal IgA Antibodies for Cancer Immunotherapy.

Authors:  Felix Hart; Antje Danielczyk; Steffen Goletz
Journal:  Bioengineering (Basel)       Date:  2017-05-08

Review 3.  IgA and FcαRI: Pathological Roles and Therapeutic Opportunities.

Authors:  Annelot Breedveld; Marjolein van Egmond
Journal:  Front Immunol       Date:  2019-03-22       Impact factor: 7.561

Review 4.  IgA: Structure, Function, and Developability.

Authors:  Patrícia de Sousa-Pereira; Jenny M Woof
Journal:  Antibodies (Basel)       Date:  2019-12-05

Review 5.  Advances in IgA glycosylation and its correlation with diseases.

Authors:  Li Ding; Xiangqin Chen; Hongwei Cheng; Tiantian Zhang; Zheng Li
Journal:  Front Chem       Date:  2022-09-27       Impact factor: 5.545

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.